ARIA‐EAACI 2025: Person‐Centred, Digitally Enabled and Artificial Intelligence‐Assisted Change Management in Airway Diseases
Jean Bousquet, Bernardo Sousa‐Pinto, Mohamed H. Shamji, Maria J. Torres, Ludger Klimek, Holger J. Schünemann, Mario Morais‐Almeida, Rafael José Vieira, Alkis Togias, Boleslaw Samolinski, Arunas Valiulis, Siân Williams, Oliver Pfaar, Torsten Zuberbier, Anna Bedbrook, Wienczyslawa Czarlewski, Maryam Ali Al‐Nesf, Rita Amaral, Josep M. Anto, Antonio Bognanni, Luisa Brussino, Alvaro A. Cruz, Violeta Kvedariene, Habib Douagui, Nikolaos G. Papadopoulos, G. Walter Canonica, Ivan Cherrez‐Ojeda, Mark Dykewicz, Bilun Gemicioglu, Mattia Giovannini, Brigita Gradauskiene, Tari Haahtela, Cristina Jacomelli, Tuomas Jartti, Miloš Jeseňák, Piotr Kuna, Désirée E. Larenas‐Linnemann, Amir H. A. Latiff, Bryan Martin, Yousser Mohammad, Kari Nadeau, Elizabete Nunes, Ken Ohta, Martial Ouédraogo, Padukudru A. Mahesh, Isabella Pali‐Schölll, Ana Margarida Pereira, Frederico S. Regateiro, Nicolas Roche, Mikhail Sofiev, Luis Taborda‐Barata, Charlotte Suppli Ulrik, Sanna K. Toppila‐Salmi, Marylin Valentin Rostan, Leticia de las Vecillas, Maria Teresa Ventura, Giovanni Viegi, De Yun Wang, He Zhang, Luo Zhang, Giorgio Ciprandi, Juan Carlos Ivancevich, Nikolai Khaltaev, Olga Lourenço, Lucas Leemann, Marine Savouré, Juan Jose Yepes‐Nuñez, Arzu Yorgancioglu, Baharudin Abdullah, Mona Al‐Ahmad, Julijana Asllani, Karl‐C. Bergmann, Jonathan A. Bernstein, Michael S. Blaiss, Fulvio Braido, Pedro Carreiro‐Martins, Lorenzo Cecchi, Antonio F. M. Giuliano, George Christoff, Ieva Cirule, Jaime Correia‐de‐Sousa, Elisio M. Costa, Biljana Cvetkovski, Stefano Del Giacco, Philippe Devillier, Dejan Dokic, Maia Gotua, Maria Antonieta Guzman, Elham Hossny, Tomohisa Iinuma, Carla Irani, Zhanat Ispayeva, Kaja Julge, Igor Kaidashev, Kazi S. Bennoor, Helga Kraxner, Inger Kull, Marek Kulus, Maciej Kupczyk, Andriy Kurchenko, Xin Luo, Stefania La Grutta, Lan Le Thi Tuyet, Michael Makris, Branislava Milenkovic, Neven Miculinic, Sang Min Lee, Stephen Montefort, André Moreira, Joaquim Mullol, Rachel Nadif, Alla Nakonechna, Hugo E. Neffen, Stefania Nicola, Marek Niedoszytko, Dieudonné Nyembue, Robyn E. O’Hehir, Ismail Ogulur, Yoshitaka Okamoto, Markus Ollert, Heidi Olze, Oscar Palomares, Petr Panzner, Hae‐Sim Park, Vincenzo Patella, Ruby Pawankar, Constantinos Pitsios, Todor A. Popov, Francesca Puggioni, Santiago Quirce, Agné Ramonaité, Marysia Recto, Maria Susana Repka‐Ramirez, Karla Robles‐Velasco, Menachem Rottem, Marianella Salapatas, Joaquin Sastre, Nicola Scichilone, Juan‐Carlos Sisul, Dirceu Solé, Manuel Soto‐Martinez, Milan Sova, Katarina Stevanovic, Pongsakorn Tantilipikorn, Ana Todo‐Bom, Vladyslav Tsaryk, Ioanna Tsiligianni, Marilyn Urrutia‐Pereira, Erkka Valovirta, Tuula Vasankari, Dana Wallace, Margitta Worm, Osman M. Yusuf, Fares Zaitoun, Mihaela Zidarn,ABSTRACT
Allergic Rhinitis and its Impact on Asthma (ARIA) was, up until 2017, a guideline using the best evidence (Grading of Recommendations, Assessment, Development and Evaluation, GRADE) and developed as a change management strategy. A second change management strategy—in collaboration with the European Academy of Allergy and Clinical Immunology (ARIA‐EAACI)—was developed as a person‐centred, digitally enabled, artificial intelligence‐assisted care (person‐centred care) with strong political involvement. The digital tools of ARIA are mainly based on MASK‐air, an Organisation for Economic Co‐operation and Development (OECD) Best Practice for integrated care for chronic diseases. Artificial intelligence was used, in particular, to approach the patients' views and expectations. The current paper describes the steps to build and achieve a new change management strategy. The future of the Change Management strategy is (i) a collaboration between ARIA and EAACI, (ii) the development of ARIA 2024‐2025 guidelines, (iii) the new ARIA‐MeDALL classification of multimorbid airway diseases and (iv) embedding MASK‐air in a registry for severe allergic diseases. The ultimate goals of the ARIA‐EAACI change management strategy will be (i) the transformation of health and care in rhinitis and asthma multimorbidity and (ii) the development of novel guidelines and policies in a cost‐effective manner, improving shared‐decision‐making.